Intravenous thromboembolism.
Conditions
Interventions
Intervention 1: In the first group, 0.5 mg/kg of enoxaparin (AVENTIS PHARMA Co., France) was injected subcutaneously in the deltoid region and rotationally the internal surface of the groin on both si
Sponsors
Zahedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Ages 18 to 70 years Hospitalization for at least 48 hours in ICU Mechanical ventilation Normal renal and hepatic function Passing 48 hours from surgery in patients with intracerebral hemorrhage (epidural , subdural and intracerebral hematoma and hemorrhagic stroke)
Exclusion criteria
Exclusion criteria: History of deep vein thrombosis History of pulmonary embolism History of coagulation disorders (hemophilia, disseminated intravascular coagulation, idiopathic thrombocytopenia, heparin- induced thrombocytopenia and disruption of coagulation tests) Treated with other anticoagulants before hospitalization Prosthetic implantation (artificial heart valve, stent and IVC filter) Myelodysplastic syndrome and other blood dyscrasias
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Active factor Xa level. Timepoint: At baseline, 4 hours after the first injection, day 10 of the study 12 hours after the last injection. Method of measurement: The measurement of active factor levels was followed up by the laboratory without the researchers' knowledge of how the test was performed. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoum khoshfetrat
Zahedan University of Medical Sciences
Outcome results
None listed